Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Tycel Phillips; Catherine Thieblemont; Herve Ghesquieres; Chan Y. Cheah; Michael Roost Clausen; David Cunningham; Young Rok Do; Tatyana A. Feldman; Robin Gasiorowski; Wojciech Jurczak; Tae Min Kim; David John Lewis; Marjolein van Der Poel; Michelle Limei Poon; Nurgul Kilavuz; Mariana Cota Stirner; David Soong; Christopher Chiu; Menghui Chen; Mariana Sacchi; Brian Elliot; Martin Hutchings; Pieternella Lugtenburg

doi:10.1182/blood-2022-158245

Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Tycel Phillips, Catherine Thieblemont, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana A. Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van Der Poel, Michelle Limei Poon, Nurgul Kilavuz, Mariana Cota Stirner, David Soong, Christopher Chiu, Menghui Chen, Mariana SacchiBrian Elliot, Martin Hutchings, Pieternella Lugtenburg

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	9443-9445
Number of pages	3
Journal	Blood
Volume	140
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2022-158245
Publication status	Published - 15 Nov 2022
Externally published	Yes
Event	64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - New Orleans, United States Duration: 10 Dec 2022 → 13 Dec 2022

Access to Document

10.1182/blood-2022-158245

Cite this

Phillips, T., Thieblemont, C., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T. A., Gasiorowski, R., Jurczak, W., Kim, T. M., Lewis, D. J., van Der Poel, M., Poon, M. L., Kilavuz, N., Stirner, M. C., Soong, D., Chiu, C., Chen, M., ... Lugtenburg, P. (2022). Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Blood, 140(Supplement 1), 9443-9445. https://doi.org/10.1182/blood-2022-158245

@article{8b43728de670422bb8344d63a10c1f4e,

title = "Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)",

author = "Tycel Phillips and Catherine Thieblemont and Herve Ghesquieres and Cheah, {Chan Y.} and Clausen, {Michael Roost} and David Cunningham and Do, {Young Rok} and Feldman, {Tatyana A.} and Robin Gasiorowski and Wojciech Jurczak and Kim, {Tae Min} and Lewis, {David John} and {van Der Poel}, Marjolein and Poon, {Michelle Limei} and Nurgul Kilavuz and Stirner, {Mariana Cota} and David Soong and Christopher Chiu and Menghui Chen and Mariana Sacchi and Brian Elliot and Martin Hutchings and Pieternella Lugtenburg",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-158245",

language = "English",

volume = "140",

pages = "9443--9445",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "Supplement 1",

note = "64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) ; Conference date: 10-12-2022 Through 13-12-2022",

}

Phillips, T, Thieblemont, C, Ghesquieres, H, Cheah, CY, Clausen, MR, Cunningham, D, Do, YR, Feldman, TA, Gasiorowski, R, Jurczak, W, Kim, TM, Lewis, DJ, van Der Poel, M, Poon, ML, Kilavuz, N, Stirner, MC, Soong, D, Chiu, C, Chen, M, Sacchi, M, Elliot, B, Hutchings, M & Lugtenburg, P 2022, 'Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)', Blood, vol. 140, no. Supplement 1, pp. 9443-9445. https://doi.org/10.1182/blood-2022-158245

Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). / Phillips, Tycel; Thieblemont, Catherine; Ghesquieres, Herve et al.
In: Blood, Vol. 140, No. Supplement 1, 15.11.2022, p. 9443-9445.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity

T2 - 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

AU - Phillips, Tycel

AU - Thieblemont, Catherine

AU - Ghesquieres, Herve

AU - Cheah, Chan Y.

AU - Clausen, Michael Roost

AU - Cunningham, David

AU - Do, Young Rok

AU - Feldman, Tatyana A.

AU - Gasiorowski, Robin

AU - Jurczak, Wojciech

AU - Kim, Tae Min

AU - Lewis, David John

AU - van Der Poel, Marjolein

AU - Poon, Michelle Limei

AU - Kilavuz, Nurgul

AU - Stirner, Mariana Cota

AU - Soong, David

AU - Chiu, Christopher

AU - Chen, Menghui

AU - Sacchi, Mariana

AU - Elliot, Brian

AU - Hutchings, Martin

AU - Lugtenburg, Pieternella

PY - 2022/11/15

Y1 - 2022/11/15

U2 - 10.1182/blood-2022-158245

DO - 10.1182/blood-2022-158245

M3 - Meeting abstract

SN - 0006-4971

VL - 140

SP - 9443

EP - 9445

JO - Blood

JF - Blood

IS - Supplement 1

Y2 - 10 December 2022 through 13 December 2022

ER -

Phillips T, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D et al. Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Blood. 2022 Nov 15;140(Supplement 1):9443-9445. doi: 10.1182/blood-2022-158245